Vireo Growth Authorizes Buyback of Up to 16.75% of Shares
VREOF sits 23% above its 52-week low of $8.91 on elevated volume (1.9× avg).
Summary
Vireo Growth's board authorized a share buyback of up to 2,426,872 subordinate voting shares (16.75% of outstanding), starting August 17, 2026.
Key Events · Financing and Capital Events · VREOF
-
Buyback Authorization
Board authorized repurchase of up to 2,426,872 subordinate voting shares, representing approximately 16.75% of issued and outstanding shares as of August 13, 2026.
-
Program Terms
NCIB commences August 17, 2026 and expires August 17, 2027. Purchases will be made on the Canadian Securities Exchange through Haywood Securities Inc. under an automatic repurchase plan.
-
Price Cap
The automatic repurchase plan permits purchases at prices up to US$18.75 per subordinate voting share, subject to pre-established trading parameters.
-
Share Count
As of August 13, 2026, the company had 48,517,509 Subordinate Voting Shares and 7,718 Multiple Voting Shares outstanding, with the Multiple Voting Shares convertible into an additional 771,800 Subordinate Voting Shares.
Analysis · VREOF · Life Sciences
The board authorized a Normal Course Issuer Bid to repurchase up to 2,426,872 subordinate voting shares, about 16.75% of the outstanding float. The program runs from August 17, 2026 to August 17, 2027, with purchases capped at US$18.75 per share. This is a meaningful capital-return signal from a company that has been aggressively acquiring assets, and it suggests management views the stock as undervalued. However, the company is under no obligation to buy any shares, and the program may be suspended or terminated at any time.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VREOF was trading at $10.98 on OTC in the Life Sciences sector, with a market capitalization of approximately $541.4M. The 52-week trading range was $8.91 to $22.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.